Vidiia was born to meet the need for rapid, cost-effective, on-site diagnostics, as highlighted by the challenges posed during the COVID-19 pandemic.The global crisis highlighted gaps in testing capacity, underscoring the need for portable, reliable diagnostics with rapid results, independent of central labs.A collaboration between the University of Surrey, Lancaster University, and Brunel University London led to Vidiia's formation, transforming their LAMP technologies, initially developed for a BBSRC-funded poultry project in the Philippines, into a COVID-19 test. The research paper (10.3389/fmolb.2023.1144001) highlights how the pandemic drove demand for fast, affordable, and accessible diagnostics, addressing critical COVID-19 testing bottlenecks and enabling broader diagnostic applications.Our COVID-19 test, developed in record time, achieved 98% sensitivity and 100% specificity, earning UK government approval under the Medical Devices Coronavirus Test Device regulations. Building on this success, Vidiia supplies agile research tools that drive translational impact and collaborates with researchers to develop new assays through our Assay Accelerator program.
Vidiia is transforming assay development and on-site diagnostics with innovative AI technology. By 2029, we aim to accelerate 100 assays through our Assay Accelerator.Our platform leverages AI to turn academic research into impactful, cost-effective diagnostics, identifying and unlocking dormant or unknown assays.
We are committed to democratising diagnostic testing with low-cost, portable, AI-powered solutions that can be used anywhere, by anyone.Vidiia identify the need to bridge research and real-world application, enhancing efficiency and ensuring global accessibility, setting new industry standards in diagnostic innovation.
